FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381330512> ?p ?o ?g. }

• W4381330512 abstract "Nebulized thrombolysis offers locally targeted therapy with potentially lower bleeding risk than systemic administration for coronavirus disease 2019 (COVID-19) respiratory failure. In a proof-of-concept safety study, adult patients with COVID-19-induced respiratory failure and a &lt;300mmHg PaO2/FiO2 (P/F) ratio, requiring invasive mechanical ventilation (IMV) or non-invasive respiratory support (NIRS) received nebulized rt-PA in two cohorts (C1 and C2), alongside standard of care during the first two UK COVID-19 waves. Matched historical controls (MHC; n=18) were used in C1. Safety co-primary endpoints were treatment-related bleeds and fibrinogen reduction to &lt;1.0–1.5 g/L. A dose escalation strategy for improved efficacy with the least safety concerns was determined in C1 for use in C2; patients were stratified by ventilation type to receive 40–60 mg rt-PA per day for ≤14 days. Nine patients in C1 (IMV, 6/9; NIRS, 3/9) and 26 in C2 (IMV, 12/26; NIRS, 14/26) received nebulized rt-PA for a mean (SD) of 6.7 (4.6) and 9.1(4.6) days, respectively. Four bleeding events (one severe and three mild) in three patients were considered treatment-related. No significant fibrinogen reductions were reported. Greater improvement in mean P/F ratio from baseline to end of study was observed in C1 compared with MHC [C1; 154 to 299 vs MHC; 154 to 212). In C2, there was no difference in the baseline P/F ratio of NIRS and IMV patients. However, a larger improvement in P/F ratio was observed in NIRS patients [NIRS; 126 to 240 vs IMV; 120 to 188) and they required fewer treatment days (NIRS; 7.86 vs IMV; 10.5). Nebulized rt-PA appears to be well-tolerated, showing a trend of improved oxygenation and faster recovery in patients with acute COVID-19-induced respiratory failure requiring respiratory support; this effect was more pronounced in the NIRS group. Further investigation is required to study the potential of this novel treatment approach." @default.
• W4381330512 created "2023-06-21" @default.
• W4381330512 creator A5000321130 @default.
• W4381330512 creator A5001719562 @default.
• W4381330512 creator A5003409008 @default.
• W4381330512 creator A5005016720 @default.
• W4381330512 creator A5006187900 @default.
• W4381330512 creator A5008277035 @default.
• W4381330512 creator A5008438810 @default.
• W4381330512 creator A5010964879 @default.
• W4381330512 creator A5012901945 @default.
• W4381330512 creator A5013116732 @default.
• W4381330512 creator A5013117957 @default.
• W4381330512 creator A5015296361 @default.
• W4381330512 creator A5016812185 @default.
• W4381330512 creator A5020839956 @default.
• W4381330512 creator A5022012717 @default.
• W4381330512 creator A5023337154 @default.
• W4381330512 creator A5026323326 @default.
• W4381330512 creator A5031163610 @default.
• W4381330512 creator A5032635874 @default.
• W4381330512 creator A5032714194 @default.
• W4381330512 creator A5033248039 @default.
• W4381330512 creator A5035620741 @default.
• W4381330512 creator A5045701251 @default.
• W4381330512 creator A5046903084 @default.
• W4381330512 creator A5048484797 @default.
• W4381330512 creator A5048558779 @default.
• W4381330512 creator A5057106591 @default.
• W4381330512 creator A5058243092 @default.
• W4381330512 creator A5058333108 @default.
• W4381330512 creator A5062420283 @default.
• W4381330512 creator A5064355731 @default.
• W4381330512 creator A5066400080 @default.
• W4381330512 creator A5068540042 @default.
• W4381330512 creator A5081183919 @default.
• W4381330512 creator A5081236203 @default.
• W4381330512 creator A5085824890 @default.
• W4381330512 creator A5086619306 @default.
• W4381330512 creator A5090253800 @default.
• W4381330512 creator A5092212642 @default.
• W4381330512 date "2023-06-20" @default.
• W4381330512 modified "2023-10-01" @default.
• W4381330512 title "Nebulized recombinant tissue plasminogen activator (rt-PA) for acute COVID-19-induced severe respiratory failure: an exploratory proof of concept trial" @default.
• W4381330512 doi "https://doi.org/10.20944/preprints202306.1455.v1" @default.
• W4381330512 hasPublicationYear "2023" @default.
• W4381330512 type Work @default.
• W4381330512 citedByCount "0" @default.
• W4381330512 crossrefType "posted-content" @default.
• W4381330512 hasAuthorship W4381330512A5000321130 @default.
• W4381330512 hasAuthorship W4381330512A5001719562 @default.
• W4381330512 hasAuthorship W4381330512A5003409008 @default.
• W4381330512 hasAuthorship W4381330512A5005016720 @default.
• W4381330512 hasAuthorship W4381330512A5006187900 @default.
• W4381330512 hasAuthorship W4381330512A5008277035 @default.
• W4381330512 hasAuthorship W4381330512A5008438810 @default.
• W4381330512 hasAuthorship W4381330512A5010964879 @default.
• W4381330512 hasAuthorship W4381330512A5012901945 @default.
• W4381330512 hasAuthorship W4381330512A5013116732 @default.
• W4381330512 hasAuthorship W4381330512A5013117957 @default.
• W4381330512 hasAuthorship W4381330512A5015296361 @default.
• W4381330512 hasAuthorship W4381330512A5016812185 @default.
• W4381330512 hasAuthorship W4381330512A5020839956 @default.
• W4381330512 hasAuthorship W4381330512A5022012717 @default.
• W4381330512 hasAuthorship W4381330512A5023337154 @default.
• W4381330512 hasAuthorship W4381330512A5026323326 @default.
• W4381330512 hasAuthorship W4381330512A5031163610 @default.
• W4381330512 hasAuthorship W4381330512A5032635874 @default.
• W4381330512 hasAuthorship W4381330512A5032714194 @default.
• W4381330512 hasAuthorship W4381330512A5033248039 @default.
• W4381330512 hasAuthorship W4381330512A5035620741 @default.
• W4381330512 hasAuthorship W4381330512A5045701251 @default.
• W4381330512 hasAuthorship W4381330512A5046903084 @default.
• W4381330512 hasAuthorship W4381330512A5048484797 @default.
• W4381330512 hasAuthorship W4381330512A5048558779 @default.
• W4381330512 hasAuthorship W4381330512A5057106591 @default.
• W4381330512 hasAuthorship W4381330512A5058243092 @default.
• W4381330512 hasAuthorship W4381330512A5058333108 @default.
• W4381330512 hasAuthorship W4381330512A5062420283 @default.
• W4381330512 hasAuthorship W4381330512A5064355731 @default.
• W4381330512 hasAuthorship W4381330512A5066400080 @default.
• W4381330512 hasAuthorship W4381330512A5068540042 @default.
• W4381330512 hasAuthorship W4381330512A5081183919 @default.
• W4381330512 hasAuthorship W4381330512A5081236203 @default.
• W4381330512 hasAuthorship W4381330512A5085824890 @default.
• W4381330512 hasAuthorship W4381330512A5086619306 @default.
• W4381330512 hasAuthorship W4381330512A5090253800 @default.
• W4381330512 hasAuthorship W4381330512A5092212642 @default.
• W4381330512 hasBestOaLocation W43813305121 @default.
• W4381330512 hasConcept C126322002 @default.
• W4381330512 hasConcept C203092338 @default.
• W4381330512 hasConcept C2776888751 @default.
• W4381330512 hasConcept C2777080012 @default.
• W4381330512 hasConcept C2779036427 @default.
• W4381330512 hasConcept C42219234 @default.
• W4381330512 hasConcept C534529494 @default.
• W4381330512 hasConcept C535046627 @default.
• W4381330512 hasConcept C71924100 @default.
• W4381330512 hasConceptScore W4381330512C126322002 @default.
• W4381330512 hasConceptScore W4381330512C203092338 @default.

• next